Cargando…
Mouse models of myeloproliferative neoplasms: JAK of all grades
In 2005, several groups identified a single gain-of-function point mutation in the JAK2 kinase that was present in the majority of patients with myeloproliferative neoplasms (MPNs). Since this discovery, much effort has been dedicated to understanding the molecular consequences of the JAK2V617F muta...
Autores principales: | Li, Juan, Kent, David G., Chen, Edwin, Green, Anthony R. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
The Company of Biologists Limited
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3097453/ https://www.ncbi.nlm.nih.gov/pubmed/21558064 http://dx.doi.org/10.1242/dmm.006817 |
Ejemplares similares
-
Myeloproliferative neoplasms and the JAK/STAT signaling pathway: an overview
por: de Freitas, Renata Mendes, et al.
Publicado: (2015) -
JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders
por: Vainchenker, William, et al.
Publicado: (2018) -
Modification of the Histone Landscape with JAK Inhibition in Myeloproliferative Neoplasms
por: Greenfield, Graeme, et al.
Publicado: (2020) -
JAK2 in Myeloproliferative Neoplasms: Still a Protagonist
por: Bader, Michael Stephan, et al.
Publicado: (2022) -
Concomitant
JAK2
mutated myeloproliferative neoplasms and hereditary hemochromatosis
por: Loscocco, Giuseppe G., et al.
Publicado: (2022)